The present invention relates to biomarkers and diagnostic and prognostic methods for Alzheimer's disease and other neurodegenerative disorders. The invention also provides compositions for detecting the biomarker as well as compositions and methods useful for treating Alzheimer's disease and other neurodegenerative disorders.

The present invention provides methods, compositions, and kits for the detection of Early-Stage Alzheimer's disease (AD) autoantibody biomarkers, for the diagnosis of Early-Stage AD, for the identification of a subject at risk for developing Early-Stage AD, and/or for the generation of patient-specific Early-Stage AD autoantibody biomarker profiles.

Disclosed are p53 peptides and their use as biomarkers in the diagnosis and/or prognosis of Alzheimer's disease (AD) in a biological sample. The invention also provides for a diagnostic method based on a highly accurate mass spectrometry analysis for the diagnosis of Alzheimer's disease at the pre-clinical and prodromal stages of the disease and for the prognosis of cognitive decline in a subject, by quantitating the levels of said p53 peptides specifically in human plasma of patients.

Disclosed are methods, kits and cells for screening an inhibitor of association between candidate binding partners, such as for screening antagonists of amyloid peptides. The methods, kits and cells employ a reporter expression cassette and hybrid proteins. The reporter expression cassette encodes a reporter and comprises at least one DNA binding site. Each hybrid protein comprises a candidate binding partner and a component of a DNA binding protein and, upon association, form a DNA-binding complex capable of binding to the at least one binding site and inhibiting expression of the reporter. The methods, kits and cells find application, for example, in the identification of inhibitors that may be useful in treating diseases associated with protein aggregation, such as Alzheimer's Disease and Parkinson's Disease.

The present disclosure relates to a method to detect or measure circRNAs in a biological sample of a subject. In particular the present disclosure is directed to a method for diagnosing a neurological, neurodegenerative, or neuropathological disease such as Alzheimer's disease, in a subject and comprises the steps of—determining the level of one or more circRNA in a sample of a biological sample of said subject.

The invention relates to sets of biomarkers and methods of use thereof for diagnosing, staging, treating, and assessing the response of a treatment for neurocognitive disorders characterised by tau toxicity, such as Alzheimer’s disease.

The present disclosure relates to methods of measuring and analyzing phosphorylation sites in the tau protein and determining correlations with other biomarkers of Alzheimer's disease and tauopathies.

Disclosed are methods of detecting abnormal expression of one or more genes associated with a neurological disease such as the Alexander disease, the Alzheimer's disease, the Parkinson disease, the Huntington disease, multiple sclerosis, and amyotrophic lateral sclerosis. The methods include performing a transcriptome analysis of the astrocytes derived from a patient and the astrocytes derived from a healthy control subject, thereby to determine one or more genes that are substantially differentially expressed. Also disclosed are methods of treating a neurological disease by correcting the abnormally expressed genes associated with the neurological disease.

The invention relates to a highly sensitive method for the detection of pGlu-Abeta (pGlu-Aβ) peptides and the use of this method in the diagnosis of neurodegenerative diseases, such as Alzheimer's disease and Mild Cognitive Impairment. The invention further concerns a novel method for monitoring the effectiveness of a treatment of neurode-generative diseases by monitoring changes in the level of pGlu-Aβ peptides.

Provided are compositions and methods useful in the diagnosis of Alzheimer's Disease (AD). The methods involve immunologically testing A B biological samples for an amount of high molecular weight kininogen (HK) and cleaved high molecular weight kininogen (HKc), wherein determining less HK relative to a normal control, or determining more HKc relative to a normal control, or a combination thereof, aids in diagnosis of AD. Hybridomas and monoclonal antibodies bind with specificity to either HK alone, or to both HK and HKc. Kits for use in immunological AD testing using the mAbs are also provided.